A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer-Reference-Cited by-同舟云学术

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

Published:2017-06 Issue: Volume:108 Page:212-216
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Wehler Thomas,Thomas Michael,Schumann Christian,Bosch-Barrera Joaquim,Viñolas Segarra Nuria,Dickgreber Nicolas J.,Dalhoff Klaus,Sebastian Martin,Corral Jaime Jesus,Alonso Miriam,Hynes Scott M.,Lin Ji,Hurt Karla,Bence Lin Aimee,Calvo Emiliano,Paz-Ares Luis

Funder

Eli Lilly and Company

Instituto de Salud Carlos III

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor;King;Invest. New Drugs,2014

2. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1day after pemetrexed 500mg/m(2) every 21days in patients with cancer;Weiss;Invest. New Drugs,2013

3. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer;Scagliotti;Invest. New Drugs,2016

4. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer;Calvo;Invest. New Drugs,2014

5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functions and inhibitors of CHK1 in cancer therapy;Medicine in Drug Discovery;2024-06

2. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity;Nature Communications;2024-05-31

3. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

4. Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background;International Journal of Molecular Sciences;2024-03-06

5. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review;Translational Lung Cancer Research;2024-02